Physician profile
Cherian A Karunapuzha
NPI 1881896397
$4,136,768.17
in general payments reported to CMS, 2019-2025
46 companies · $612K in 2025
The $612K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731K · 2020: $425K · 2021: $557K · 2022: $644K · 2023: $649K · 2024: $519K · 2025: $612K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.2M · Travel and Lodging: $212K · Honoraria: $183K · Consulting Fee: $119K · Food and Beverage: $32K · Education: $1,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,232,911.32 |
| Travel and Lodging | $211,559.59 |
| Honoraria | $182,614.75 |
| Consulting Fee | $119,036.15 |
| Food and Beverage | $32,113.86 |
| Education | $1,850.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,097,766.07 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $703,004.29 | 2019-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $656,351.28 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Acadia Pharmaceuticals INC | $474,658.09 | 2019-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $408,968.33 | 2019-2025 | Crexont, Ongentys, Rytary |
| Kyowa Kirin, INC. | $299,185.94 | 2019-2025 | Nourianz |
| Abbvie INC. | $158,545.65 | 2021-2025 | |
| Adamas Pharmaceuticals, INC. | $153,885.83 | 2019-2021 | |
| Acorda Therapeutics, INC | $89,680.09 | 2019-2024 | Inbrija, Ampyra |
| Allergan, INC. | $27,250.00 | 2019-2022 | |
| Lundbeck LLC | $26,758.65 | 2019-2025 | Rexulti |
| Merz Pharmaceuticals, LLC | $15,496.87 | 2021-2025 | Xeomin, Inbrija |
| Merz North America, INC. | $11,591.95 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $6,430.13 | 2022-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $3,019.69 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherian Karunapuzha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.